JP2003512434A - 残された腎機能を有する慢性腎不全を治療するためのウロジラチンの使用 - Google Patents
残された腎機能を有する慢性腎不全を治療するためのウロジラチンの使用Info
- Publication number
- JP2003512434A JP2003512434A JP2001532793A JP2001532793A JP2003512434A JP 2003512434 A JP2003512434 A JP 2003512434A JP 2001532793 A JP2001532793 A JP 2001532793A JP 2001532793 A JP2001532793 A JP 2001532793A JP 2003512434 A JP2003512434 A JP 2003512434A
- Authority
- JP
- Japan
- Prior art keywords
- urodilatin
- renal failure
- chronic renal
- dialysis
- residual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010001957 Ularitide Proteins 0.000 title claims abstract description 23
- 102400001279 Urodilatin Human genes 0.000 title claims abstract description 23
- IUCCYQIEZNQWRS-DWWHXVEHSA-N ularitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 IUCCYQIEZNQWRS-DWWHXVEHSA-N 0.000 title claims abstract description 23
- 208000020832 chronic kidney disease Diseases 0.000 title claims abstract description 17
- 208000022831 chronic renal failure syndrome Diseases 0.000 title claims abstract description 17
- 230000003907 kidney function Effects 0.000 title claims abstract description 10
- 230000004936 stimulating effect Effects 0.000 claims abstract 2
- 238000000502 dialysis Methods 0.000 claims description 18
- 230000002485 urinary effect Effects 0.000 claims description 7
- 239000002699 waste material Substances 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 101000835998 Homo sapiens SRA stem-loop-interacting RNA-binding protein, mitochondrial Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 102100025491 SRA stem-loop-interacting RNA-binding protein, mitochondrial Human genes 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001084 renoprotective effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19951471A DE19951471A1 (de) | 1999-10-26 | 1999-10-26 | Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen |
| DE19951471.2 | 1999-10-26 | ||
| PCT/EP2000/010462 WO2001030376A2 (de) | 1999-10-26 | 2000-10-24 | Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003512434A true JP2003512434A (ja) | 2003-04-02 |
| JP2003512434A5 JP2003512434A5 (enExample) | 2008-11-13 |
Family
ID=7926884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001532793A Pending JP2003512434A (ja) | 1999-10-26 | 2000-10-24 | 残された腎機能を有する慢性腎不全を治療するためのウロジラチンの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6831064B1 (enExample) |
| EP (1) | EP1223968B1 (enExample) |
| JP (1) | JP2003512434A (enExample) |
| AT (1) | ATE239497T1 (enExample) |
| DE (2) | DE19951471A1 (enExample) |
| ES (1) | ES2198359T3 (enExample) |
| WO (1) | WO2001030376A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2392892T3 (es) | 2005-04-07 | 2012-12-14 | Cardiopep Pharma Gmbh | Uso de un péptido natriurético para tratar insuficiencia cardiaca |
| US20080181903A1 (en) * | 2006-12-21 | 2008-07-31 | Pdl Biopharma, Inc. | Conjugate of natriuretic peptide and antibody constant region |
| ES2575397T3 (es) * | 2007-09-11 | 2016-06-28 | Cardiopep Pharma Gmbh | Uso de péptidos natriuréticos para el tratamiento de síndromes de angioedema |
| EP2078530A1 (en) | 2008-01-08 | 2009-07-15 | Pharis Biotec GmbH | Use of natriuretic peptides for treating angioedema syndromes |
| WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| EP2948165A2 (en) | 2013-01-25 | 2015-12-02 | Cardiorentis Ltd. | A natriuretic peptide, a diuretic peptide or a vasodilatory peptide for use in methods of treating cardiovascular indications |
| WO2022029499A1 (en) | 2020-08-06 | 2022-02-10 | Ads Aiphia Development Services Ag | Methods of treating refractory ascites |
| WO2022029497A1 (en) | 2020-08-06 | 2022-02-10 | Ads Aiphia Development Services Ag | Ularitide for use in methods of treating refractory ascites |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02502636A (ja) * | 1987-03-02 | 1990-08-23 | ファーマ・ビッセンドルフ・ペプタイド・ゲーエムベーハー | 新規なカルジオジラチン断片およびその製造方法 |
| WO1998029434A1 (en) * | 1996-12-31 | 1998-07-09 | Ford Henry Health System | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
| JPH11505265A (ja) * | 1995-05-22 | 1999-05-18 | ジェネンテック インコーポレーテッド | Ｉｇｆ−ｉの投与法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691310A (en) | 1987-09-29 | 1997-11-25 | Vesely; David L. | Methods of treatment using proANF peptides |
| DE4216133A1 (de) * | 1992-05-15 | 1993-11-18 | Bissendorf Peptide Gmbh | Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen |
| US5565428A (en) * | 1995-05-22 | 1996-10-15 | Genentech, Inc. | Method of administration of IGF-I |
-
1999
- 1999-10-26 DE DE19951471A patent/DE19951471A1/de not_active Withdrawn
-
2000
- 2000-10-24 ES ES00975905T patent/ES2198359T3/es not_active Expired - Lifetime
- 2000-10-24 WO PCT/EP2000/010462 patent/WO2001030376A2/de not_active Ceased
- 2000-10-24 DE DE50002119T patent/DE50002119D1/de not_active Expired - Lifetime
- 2000-10-24 AT AT00975905T patent/ATE239497T1/de not_active IP Right Cessation
- 2000-10-24 JP JP2001532793A patent/JP2003512434A/ja active Pending
- 2000-10-24 US US10/088,498 patent/US6831064B1/en not_active Expired - Lifetime
- 2000-10-24 EP EP00975905A patent/EP1223968B1/de not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02502636A (ja) * | 1987-03-02 | 1990-08-23 | ファーマ・ビッセンドルフ・ペプタイド・ゲーエムベーハー | 新規なカルジオジラチン断片およびその製造方法 |
| JPH11505265A (ja) * | 1995-05-22 | 1999-05-18 | ジェネンテック インコーポレーテッド | Ｉｇｆ−ｉの投与法 |
| WO1998029434A1 (en) * | 1996-12-31 | 1998-07-09 | Ford Henry Health System | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
Non-Patent Citations (1)
| Title |
|---|
| JPN6010052795, ＭＥＹＥＲ，Ｍ． ｅｔ ａｌ, "Ｕｒｏｄｉｌａｔｉｎ （ＩＮＮ：ｕｌａｒｉｔｉｄｅ） ａｓ ａ ｎｅｗ ｄｒｕｇ ｆｏｒ ｔｈｅ ｔｈｅｒａｐｙ ｏｆ ａｃｕｔｅ ｒｅｎａｌ ｆａｉｌｕｒｅ ｆｏｌｌｏｗｉｎｇ ｃａｒｄｉａｃ ｓｕ", Ｃｌｉｎ Ｅｘｐ Ｐｈａｒｍａｃｏｌ Ｐｈｙｓｉｏｌ, 1997, Ｖｏｌ．２４， Ｎｏ．５, ｐ．３７４−６ * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001030376A2 (de) | 2001-05-03 |
| DE50002119D1 (de) | 2003-06-12 |
| ATE239497T1 (de) | 2003-05-15 |
| EP1223968A2 (de) | 2002-07-24 |
| ES2198359T3 (es) | 2004-02-01 |
| WO2001030376A3 (de) | 2001-12-06 |
| EP1223968B1 (de) | 2003-05-07 |
| DE19951471A1 (de) | 2001-05-03 |
| US6831064B1 (en) | 2004-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6425A (en) | Medicinal composition for treating hiv infection containing dsrna and reverse transcriptase inhibitor | |
| KR20050055053A (ko) | 만성 Ｃ형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-α 및 리바비린의 용도 | |
| IL135712A0 (en) | Methods for treating hypercoagulable states or acquired protein c deficiency | |
| KR890012666A (ko) | 신장 질환의 치료방법 | |
| CA2185998A1 (en) | The combination of growth hormone and insulin-like growth factor, for treating congestive heart failure | |
| US4794103A (en) | Pharmaceutical compositions containing peptides of the cholecystokinin-cerulein group for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies | |
| JP2003512434A (ja) | 残された腎機能を有する慢性腎不全を治療するためのウロジラチンの使用 | |
| MD1875F1 (en) | Method of treatment of the acute viral hepatitis B | |
| Harning et al. | A treatment for metastasis of murine ocular melanoma. | |
| JPWO1999018993A1 (ja) | Ｃ型肝炎治療効果の改善剤及びその応用 | |
| MX9704502A (es) | Tratamiento de enfermedad autoinmune usando derivados de 2-amino purina. | |
| US5380710A (en) | Pharmaceutical compositions containing ACTH (1-24) for the therapy of shock conditions and respiratory and cardiocirculatory insufficiences | |
| US20040037896A1 (en) | Therapeutic treatment | |
| AU2002220960A1 (en) | Regeneration of blood vessels | |
| NZ514629A (en) | PEGylated interferon-alpha administered at about 4.5- 9.0 micrograms/kg/week as a renal cell carcinoma treatment | |
| Viskoper et al. | The antihypertensive effect of atenolol and bopindolol in the elderly | |
| Izzedine et al. | Pharmacokinetics of ritonavir and saquinavir in a haemodialysis patient | |
| TWI263502B (en) | Pharmaceutical preparation for treating ischemic disease of heart or limbs | |
| Gavras et al. | ACE inhibitors: a decade of clinical experience | |
| James | Ribavirin approved for hepatitis C combination treatment | |
| LT2006024A (en) | Tetrapeptide regulating blood glucose level in diabetes mellitus | |
| JP2857388B1 (ja) | アカメガシワ樹皮のエキスを有効成分とする肝機能改善剤、肝機能改善飲料、及び肝機能改善茶 | |
| Mizerski et al. | Flozins, inhibitors of type 2 renal sodium-glucose co-transporter–not only antihyperglycemic drugs | |
| Rosenthal | Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy | |
| JPH0251405B2 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070920 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080924 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100914 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110222 |